CMHC (CMHC) News
Follow CMHC (CMHC) news in one place: company catalysts, earnings, analyst actions and wider market developments. Review 3 public stories across 2 publication days to understand how the story developed. Public news appears after a 15-minute delay; LiveCast subscribers can follow new headlines and hear important updates without this additional delay.
M
Cosmo’s Rifamycin Gel Meets Phase 2 Remission Endpoint
Cosmo reported remission in 46.2% of patients versus 14.3% on placebo (p=0.0190). It plans FDA and EMA discussions and to advance toward Phase 3.
EQUITY | Oct 19, 2026, 05:11 AM UTC
M
Cosmo Reports Phase 2 Study Met Primary Endpoint in Colitis
Cosmo announced topline Phase 2 results for rifamycin 1% topically acting gel in distal ulcerative colitis and ulcerative proctitis.
EQUITY | Oct 19, 2026, 05:11 AM UTC
M
GI Genius availability linked to higher adenoma detection odds
Cosmo N.V. said a VHA cluster-randomized study of 334K colonoscopies found GI Genius availability was associated with 22% higher odds of detecting an adenoma, with adenoma detection rising from 50.7% to 54.9% at CADe sit
EQUITY | Sep 21, 2026, 05:11 AM UTC